The invention concerns a process for preparing an allograft or xenograft material from a lens capsule, wherein the process comprises the following steps: Decellularizing (200) a lens capsule to obtain a decellularized lens capsule, Depositing (300) the decellularized capsule on a microporous support membrane to obtain a stack composed of the decellularized lens capsule and the support membrane, Lyophilizing (400) the stack to obtain a lyophilized stack, Sterilizing (500) the lyophilized stack to obtain a sterilized stack, Packaging (600) the sterilized stack to obtain allograft or xenograft materials.

The present invention discloses an artificial endothelial keratoplasty graft consisting a support layer made of rehydrated crosslinked hydrogel and corneal endothelial cells on top or within said support layer. The invention also discloses a method of manufacturing an artificial endothelial keratoplasty graft, wherein said method consisting of a step of drying support layer material followed by a crosslinking step.

The application describes a contractile cellular biomaterial that is particularly well suited to regenerative therapy of tissue affected by myocardial infraction. The biomaterial comprises a contractile tissue which is contained in an optionally porous solid substrate. The contractile tissue is formed by differentiating stem cells, in particular mesenchymal stem cells. In addition to being contractile, the biomaterial can have inducible paracrine activity. The biomaterial has, in particular, the advantage of not needing to be frozen in order to be conserved.

The disclosure provides a method of using blood or fractions thereof, e.g., serum, obtained from a mammal subjected to liver surgery, for example, obtained following a partial hepatectomy, to increase the engraftment, proliferation and/or functionality of cells on a biocompatible scaffold.

A modular engineered tissue construct includes a plurality of fused self-assembled, scaffold-free, high-density cell aggregates. At least one cell aggregate includes a plurality of cells and a plurality of biocompatible and biodegradable nanoparticles and/or microparticles that are incorporated within the cell aggregates. The nanoparticles and/or microparticles acting as a bulking agent within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate as well as to deliver bioactive agents.

Provided herein are methods and systems of transplant cells and growing an ectopic tissue in a lymph node of a subject. In certain embodiments, the methods and systems provided herein enable minimally invasive cell transplantation to treat patients in need thereof In certain embodiments, the methods and systems provided herein include the use of ultrasound endoscopy.

Described herein are electrospun nanofiber structures and compositions configured to serve as TNT-based platforms for the delivery of an agent or cargo, such as genetic material. The structures can include a conductive nanofiber comprising a shell electrospun from an insulating polymer, wherein the shell comprises a plurality of nanochannels therethrough, a conductive element, and an agent contained within the shell. The conductive nanofiber can be configured to deliver the agent when exposed to an electric field. The agent can include a therapeutic agent, a prophylactic agent, or a diagnostic agent.

The invention provides for methods and materials to decellularize an organ or portion thereof and to recellularize such a decellularized organ or portion thereof to thereby generate an organ or portion thereof.

The present disclosure is related to a perfusable-type bio-dual proximal tubule cell construct and a producing method thereof capable of applying an in vitro artificial organ model configured to include a first bioink comprising a decellularized substance derived from a mammalian kidney tissue and human umbilical vascular endothelial cells (HUVECs) and a second bioink comprising the decellularized substance and renal proximal tubular epithelial cells (RPTECs), wherein the first bioink and the second bioink are coaxial and printed in tubular constructs having different inner diameters.

According to the present disclosure, it is possible to use the renal proximal tubule-on-a-chip as a bioreactor capable of observing a biological drug reaction similar to a real drug by perfusing various drugs to the renal proximal tubule-on-a-chip.

A method of producing bioengineered tissue includes coating a microstructured fiber with a bioink containing a plurality of living cells. The microstructured fiber is embedded with microfluidic channels defining periodic outlet apertures, a plurality of ultrasonic transducers, at least one chemical sensor, and at least one temperature sensor. The method further includes applying the coated fiber to an anatomic model of an organ. The microfluidic channels and outlet apertures of the fiber are configured to function as an artificial blood-vessel system to the bioengineered tissue, thereby supplying building material for the proliferation of the plurality of living cells, and allowing the bioengineered tissue to mature into functional tissue.